Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,955 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Investigational drug Clear all
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

NCT01339559
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT04203342
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

NCT03719586
View directory record Official record
Conditions
Ebola Virus
Interventions
ZMapp, Remdesivir, MAb114, REGN-EB3
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 99 Years
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 18, 2026, 3:32 AM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT07689188
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foam
Drug
Lead sponsor
Harrison Dermatology
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Missouri City, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 18, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097
View directory record Official record
Conditions
Rectal Cancer
Interventions
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 18, 2026, 3:32 AM EDT
Active, not recruiting Not applicable Interventional

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820
View directory record Official record
Conditions
Pompe Disease (Late-onset)
Interventions
No Intervention
Other
Lead sponsor
Astellas Gene Therapies
Industry
Eligibility
16 Years to 69 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Atlanta, Georgia • Kansas City, Kansas • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Evaluating the Effectiveness of a Chronic Disease Management Program for Gout

NCT01568879
View directory record Official record
Conditions
Recurrent or Tophaceous Gout
Interventions
Control, Gout Disease Management Program
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
All KPNC Facilities, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SEEK: Dissemination and Implementation

NCT03642327
View directory record Official record
Conditions
Child Maltreatment
Interventions
Experimental: Maintenance of Certification (MOC), Independent online training (IND)
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

Physical Therapy and Deep Brain Stimulation in Parkinson Disease

NCT03181282
View directory record Official record
Conditions
Parkinson Disease
Interventions
Physical Therapy
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 18, 2026, 3:32 AM EDT
Terminated Phase 4 Interventional Results available

Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses

NCT03040323
View directory record Official record
Conditions
Liver Biopsy
Interventions
Lumason 60.7Mg Powder for Injection, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 18, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 18, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

NCT02816346
View directory record Official record
Conditions
Healthy
Interventions
Shigella sonnei 53G
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 18, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Antithrombin (Recombinant), Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Days to 30 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 18, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial Tears
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)

NCT02025179
View directory record Official record
Conditions
Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Teriparatide, Vibration
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 18, 2026, 3:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

NCT03013491
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
CX-072, ipilimumab, vemurafenib
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 18, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

NCT06366503
View directory record Official record
Conditions
Photoaging, Wrinkle, Skin Laxity
Interventions
Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Blue Ash, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 18, 2026, 3:32 AM EDT